Company: DARE
Filing Date: 2025-07-25
Form Type: 8-K
Source: 0001493152-25-011402
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-07-25
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
July 24, 2025, Daré Bioscience, Inc. (“ Daré,” “we,” “us,” “our” or the
“ Company”) received a letter from the Nasdaq Office of General Counsel confirming that the Company demonstrated compliance
with the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) (the “ Stockholders’ Equity Rule”),
and that the Company is therefore in compliance with the Nasdaq Capital Market’s continued listing requirements.

That
letter also informed us that, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), we will be subject to a Mandatory Panel Monitor for a period
of one year from July 24, 2025, and that if, within that one-year period, the Nasdaq Listing Qualifications Staff (the “ Staff”)
determines that we are out of compliance with the Stockholders’ Equity Rule, the Staff will issue a delist determination letter
and we will have an opportunity to request a new hearing with Nasdaq’s Hearings Panel. Notwithstanding Nasdaq Listing Rule 5810(c)(2),
we will not be permitted to provide a plan of compliance to the Staff with respect to such non-compliance, the Staff will not be permitted
to grant additional time for us to regain compliance, and we will not be afforded a cure period pursuant to Nasdaq Listing Rule 5810(c)(3).

  -2-  

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     DARÉ                                               
  Dated:             By:                   /s/                          
                     Name:                 Sabrina                      
                     Title:                President                    

  -3-